[go: up one dir, main page]

MX2023010078A - Aplicación del inhibidor de apoptosis 5 (api5) para la restitución epitelial. - Google Patents

Aplicación del inhibidor de apoptosis 5 (api5) para la restitución epitelial.

Info

Publication number
MX2023010078A
MX2023010078A MX2023010078A MX2023010078A MX2023010078A MX 2023010078 A MX2023010078 A MX 2023010078A MX 2023010078 A MX2023010078 A MX 2023010078A MX 2023010078 A MX2023010078 A MX 2023010078A MX 2023010078 A MX2023010078 A MX 2023010078A
Authority
MX
Mexico
Prior art keywords
api5
recombinant
proteins
application
apoptosis inhibitor
Prior art date
Application number
MX2023010078A
Other languages
English (en)
Inventor
Shohei Koide
Akiko Koide
Kenneth Cadwell
Yu Matsuzawa-Ishimoto
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of MX2023010078A publication Critical patent/MX2023010078A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción proporciona, entre otras cosas, proteínas API5 recombinantes y ácidos nucleicos aislados que las codifican. También se proporcionan vectores que comprenden los ácidos nucleicos y células hospedadoras que comprenden los vectores o ácidos nucleicos que codifican las proteínas API5 recombinantes. Además, se proporcionan composiciones que comprenden estas proteínas recombinantes, y métodos de uso de estas proteínas recombinantes para la restitución epitelial y el tratamiento de enfermedades y trastornos relacionados.
MX2023010078A 2021-03-05 2022-03-07 Aplicación del inhibidor de apoptosis 5 (api5) para la restitución epitelial. MX2023010078A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163157225P 2021-03-05 2021-03-05
PCT/US2022/019138 WO2022187738A1 (en) 2021-03-05 2022-03-07 Application of apoptosis inhibitor 5 (api5) for epithelial restitution

Publications (1)

Publication Number Publication Date
MX2023010078A true MX2023010078A (es) 2023-11-09

Family

ID=83154664

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010078A MX2023010078A (es) 2021-03-05 2022-03-07 Aplicación del inhibidor de apoptosis 5 (api5) para la restitución epitelial.

Country Status (10)

Country Link
US (1) US20240317829A1 (es)
EP (1) EP4301471A1 (es)
JP (1) JP2024509540A (es)
CN (1) CN118159569A (es)
AU (1) AU2022229921A1 (es)
BR (1) BR112023017843A2 (es)
CA (1) CA3210274A1 (es)
CO (1) CO2023011603A2 (es)
MX (1) MX2023010078A (es)
WO (1) WO2022187738A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076309B2 (en) * 2008-04-30 2011-12-13 New York University USP47 inhibtors and methods to induce apoptosis
EP3107932B1 (en) * 2014-02-17 2019-12-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides for the treatment of cancer
US20160202242A1 (en) * 2014-12-26 2016-07-14 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth

Also Published As

Publication number Publication date
CA3210274A1 (en) 2022-09-09
CO2023011603A2 (es) 2023-09-18
BR112023017843A2 (pt) 2023-12-05
EP4301471A1 (en) 2024-01-10
AU2022229921A1 (en) 2023-09-14
US20240317829A1 (en) 2024-09-26
JP2024509540A (ja) 2024-03-04
CN118159569A (zh) 2024-06-07
WO2022187738A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
WO2021087296A8 (en) Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
ZA202501799B (en) Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
MY193353A (en) Anti-vegf protein compositions and methods for producing the same
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
MY191030A (en) Gdf15 fusion proteins and uses thereof
WO2022256500A3 (en) Dll3 targeting trispecific proteins and methods of use
WO2019209965A3 (en) Interleukin 12 fusion proteins, and compositions and therapeutic methods thereof
MY120693A (en) Human bikunin
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
PH12022550693A1 (en) Multi-specific binding proteins for cancer treatment
WO2020163743A8 (en) Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
WO2020214809A3 (en) Gene therapies for stargardt disease (abca4)
MX2025009545A (es) Metodos y composiciones para la administracion de sistemas de vector dual otoferlin
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
PH12022553408A1 (en) Cytokine conjugates
ATE532861T1 (de) Expressionsvektor
MX2023010078A (es) Aplicación del inhibidor de apoptosis 5 (api5) para la restitución epitelial.
MX2025012376A (es) Métodos y composiciones farmacéuticas de apoe para el tratamiento y la prevención de enfermedad de alzheimer
AU2020313981A8 (en) Factor H potentiating antibodies and uses thereof
WO2020214820A3 (en) Aim2 inhibitors and uses thereof
WO2020210480A3 (en) Factor h vectors and uses thereof
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
MX2023015400A (es) Variantes de interleucina 15.
WO2022248651A3 (en) Inhibitory nucleic acids for factor h family proteins